Genmab | GEN - Current Liabilities


Genmab reported DKK1.43B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Amgen USD 24.96B 534M Mar/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 33.46B 875M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Demant DKK 7.42B 1.63B Dec/2025
Exelixis USD 370.98M 34.67M Mar/2026
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GN Store Nord DKK 4.81B 2.5B Mar/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Insmed USD 361.01M 107.87M Mar/2026
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025